P. Souza

发表

Dietary Manipulation for Therapeutic Effect in Prostate Cancer

J. Bucci, H. Greenfield, K. Scott, 2012 .

Droplet Digital PCR Based Detection of EGFR Mutations in Advanced Lung Cancer Patient Liquid Biopsies: A Comparison of Circulating Tumour DNA Extraction Kits

T. Becker, P. Ding, V. Bray, 2018 .

Long-term safety and efficacy analysis of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (COU-AA-302).

J. Hainsworth, H. Scher, J. Bono, 2013 .

New frontiers in circulating tumor cell analysis: A reference guide for biomolecular profiling toward translational clinical use

T. Becker, N. Kienzle, A. Tognela, 2014, International journal of cancer.

ATIM-47. NIVOLUMAB VS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: EXPLORATORY ANALYSIS OF MGMT METHYLATION STATUS AND BASELINE CORTICOSTEROID USE

M. Weller, A. Brandes, M. Ahluwalia, 2019, Neuro-Oncology.

Chinese Herbal Medicine to Alleviate Vasomotor Symptoms in Breast Cancer Survivors: A Study Protocol for a Randomised, Double Blind, Placebo Controlled, Multi Centre, Cross Over Trial

P. Fahey, A. Bensoussan, Xiaoshu Zhu, 2020 .

Docetaxel-related fatigue in men with metastatic prostate cancer: a descriptive analysis

E. Hovey, A. Lloyd, P. Parente, 2017, Supportive Care in Cancer.

Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

J. Carles, H. Scher, J. Bono, 2012 .

Circulating tumour cells—a bona fide cause of metastatic cancer

T. Becker, N. Kienzle, A. Tognela, 2014, Cancer and Metastasis Reviews.

Prognostic factors in ovarian cancer.

M. Friedlander, M. Friedlander, A. Dembo, 1992, Seminars in oncology.

Final analysis of COMET-2: Cabozantinib (Cabo) versus mitoxantrone/prednisone (MP) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with moderate to severe pain who were previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).

E. Basch, H. Scher, J. Bono, 2015 .

Circulating tumour cells and the epithelial mesenchymal transition in colorectal cancer

T. Becker, W. Chua, P. de Souza, 2014, Journal of Clinical Pathology.

Health professionals’ opinions on supporting a cancer biobank: identification of barriers to combat biobanking pitfalls

Joseph Descallar, J. Descallar, Janelle V Levesque, 2015, European Journal of Human Genetics.

Circulating tumour cells and circulating free nucleic acid as prognostic and predictive biomarkers in colorectal cancer.

J. Rasko, T. Becker, W. Chua, 2014, Cancer letters.

Association of Radiographic Progression-Free Survival (RPFS) Adapted from Prostate Cancer Working Group 2 (PCWG2) Consensus Criteria (APCWG2) with Overall Survival (OS) in Patients (PTS) with Metastatic Castration-Resistant Prostate Cancer (MCRPC): Results from COU-AA-302

S. Larson, M. Morris, H. Scher, 2012 .